Chen received her doctorate at Hebei Medical University China in Cardiovascular Physiology. After post-doctoral studies at Harbor-UCLA investigating the nitric oxide and GABA signal transduction in the somatosympathetic reflexes and their cardiovascular control mechanisms, Chen joined the lab of Moshe Arditi, MD, studying varying aspects of innate immunity, Chlamydia pneumoniae infection, and atherosclerosis. Chen has received an AHA Grant-in-Aid Award and has recently been awarded her first R01 from the NIH to investigate the role of IL-17 and the NLRP3 inflammasome activation in atherogenesis.
Crother received his doctorate at Indiana University in Molecular, Cellular, and Developmental Biology. After post-doctoral studies at UCLA investigating the pathogenesis of Borrelia burgdorferi (the causative agent of Lyme disease), Crother joined the lab of Moshe Arditi, MD, studying varying aspects of innate immunity, Chlamydia pneumoniae infection and asthma.
Shimada received his PhD in Microbiology and Immunology at Kitasato University. Shimada joined the Arditi Laboratory and is now studying host defenses against pathogens, innate immunity, and immune regulation. Shimada made the seminal observation that oxidized mitochondrial DNA during apoptosis is released and binds to cytosolic NLRP3 to activate it for IL-1 beta production (immunity paper). Shimada is now investigating the mitochondria and NLRP3 inflammasome activation mechanisms, acute lung injury and the role of Rip2 and Th17 in Chlamydia pneumoniae infections.
Jones received her medical degree from the Medical College of Pennsylvania/Hahnemann University and completed her residency in Internal Medicine at Boston Medical Center. After residency, she trained in pulmonary and critical care at Johns Hopkins Hospital and completed her research fellowship training at the National Heart, Lung, and Blood Institute of the National Institutes of Health. She is a faculty member in the Division of Pulmonary and Critical Care Medicine and the Medical Director of a Medical-Surgical Intensive Care Unit at Cedars-Sinai. Jones is interested in the immunological mechanisms responsible for the development of ventilator-induced acute lung injury and in potential therapeutic agents to modulate this disease, and conducts her research in the Arditi Laboratory
Dagvadorj received his doctorate at Aichi Medical University, Japan, where he studied the regulatory role of IL-10 on Toll-like receptor (TLR) signaling pathways. He joined Arditi Laboratory and is currently studying bacterial agent-induced activation of the innate immune system and TLR signaling. He has generated the MyD88-Tie2 cre-floxed mice and is investigating the role of vascular EC MYD88 in LPS-induced acute lung injury in the Arditi lab.
Tumurkhuu received her doctorate in Immunology in 2008 from Aichi Medical University, Japan. Her research was focused on the function, signal transduction pathways and regulation of Toll-like Receptors (TLR), especially LPS-mediated activation of innate immunity and septic shock. Her current studies involve the molecular pathogenesis of infection and immunity in atherosclerotic development.
Wakita received his PhD from Hokkaido University investigating the regulatory mechanisms of tumor-inhibiting and tumor-promoting immune responses during cancer development. He is an accomplished tumor immunologist. Since joining Arditi Laboratory, he is investigating the molecular mechanisms involved in the development of vasculitis in the Kawasaki disease mouse model. He is also investigating the innate immune mechanism and vascular signaling during lung cancer metastasis.
Harry Matundan, PhD, received his doctorate in biomedical sciences conferred by the Department of Biological Chemistry in the School of Medicine, of the University of California, Irvine. He focused on novel mechanisms of drug resistance in human malignant melanoma. Prior to joining the Arditi Laboratory, he worked on the role of the immune system on HSV-1 challenged immunized mice. Currently in the Arditi Lab, Matundan is studying the pathogenesis mechanisms of Kawasaki disease using a novel mouse model and the contributions of the nervous system to its pathology.
Janet Markman received her master’s degree in bioscience technologies from Thomas Jefferson University. After studying nanomedicine-based treatments for metastatic and resistant tumors, Markman was accepted into the Biomedical Science and Translational Medicine Program and joined the Arditi Laboratory where she is studying the relationships between innate immunity, hormonal signaling and cancer.